Patient baseline characteristics
| Characteristics . | Training cohort (n = 522) . | Validation cohort (n = 262) . | Total cohort (N = 784) . |
|---|---|---|---|
| Age, y | |||
| Median (range) | 79 (70-100) | 78 (70-93) | 79 (70-100) |
| 70-74 | 132 (25) | 70 (27) | 202 (26) |
| 75-79 | 137 (26) | 79 (30) | 216 (28) |
| 80-84 | 149 (29) | 68 (26) | 217 (28) |
| ≥85 | 104 (20) | 45 (17) | 149 (19) |
| Sex | |||
| Female | 248 (48) | 131 (50) | 379 (48) |
| Male | 274 (52) | 131 (50) | 405 (52) |
| Stage (Ann Arbor) | |||
| I | 103 (20) | 44 (17) | 147 (19) |
| II | 132 (25) | 67 (25) | 199 (25) |
| III | 78 (15) | 38 (15) | 116 (15) |
| IV | 206 (40) | 111 (43) | 317 (41) |
| Missing | 3 | 2 | 5 |
| LDH | |||
| Normal | 227 (45) | 112 (46) | 339 (46) |
| Elevated | 273 (55) | 131 (54) | 404 (54) |
| Missing | 22 | 19 | 41 |
| ECOG PS | |||
| 0 | 119 (23) | 38 (15) | 157 (21) |
| 1 | 142 (28) | 88 (36) | 230 (30) |
| 2 | 118 (23) | 55 (22) | 173 (23) |
| 3 | 104 (21) | 51 (21) | 155 (20) |
| 4 | 27 (5) | 15 (6) | 42 (6) |
| Missing | 12 | 15 | 27 |
| Extranodal sites | |||
| 0-1 | 401 (77) | 198 (76) | 599 (77) |
| ≥ 2 | 118 (23) | 63 (24) | 181 (23) |
| Missing | 3 | 1 | 4 |
| IPI score | |||
| Low (1) | 107 (22) | 43 (18) | 150 (21) |
| Low-intermediate (2) | 93 (19) | 61 (26) | 154 (21) |
| High-intermediate (3) | 130 (26) | 54 (23) | 184 (25) |
| High (4-5) | 162 (33) | 78 (33) | 240 (33) |
| Missing | 30 | 26 | 56 |
| ADL | |||
| Independent | 375 (72) | 184 (71) | 559 (72) |
| Dependent | 146 (28) | 75 (29) | 221 (28) |
| Missing | 1 | 3 | 4 |
| CCI | |||
| 0-1 | 311 (60) | 173 (66) | 484 (62) |
| 2 | 106 (20) | 39 (15) | 145 (19) |
| ≥3 | 104 (20) | 50 (19) | 154 (20) |
| Missing, n | 1 | 0 | 1 |
| GNRI | |||
| Absent/low | 300 (63) | 135 (60) | 435 (61) |
| Moderate | 113 (24) | 46 (20) | 159 (23) |
| Severe | 64 (13) | 45 (20) | 109 (16) |
| Missing | 45 | 36 | 81 |
| BMI, kg/m2 | |||
| ≥25 | 271 (58) | 119 (53) | 390 (56) |
| <25 | 198 (42) | 104 (47) | 302 (44) |
| Missing, n | 53 | 39 | 92 |
| Albumin | |||
| ≥36 g/L | 283 (55) | 132 (53) | 415 (54) |
| <36 g/L | 235 (45) | 116 (47) | 351 (46) |
| Missing, n | 4 | 14 | 18 |
| Treatment regimen | |||
| R-CHOP like* | 313 (60) | 169 (65) | 482 (62) |
| R-CHOP > 80% | 202 (39) | 103 (39) | 305 (39) |
| R-CHOP ≤ 80% | 111 (21) | 65 (25) | 176 (22) |
| Missing, n | 0 | 1 | 1 |
| Anthracycline-free regimen† | 96 (18) | 49 (19) | 145 (19) |
| Trofosfamide (Ixoten) | 51 (10) | 18 (7) | 69 (9) |
| R-COP | 36 (7) | 27 (10) | 63 (8) |
| R-CEOP | 3 (0.5) | 1 (0.5) | 4 (0.5) |
| Other‡ | 6 (1) | 3 (1) | 9 (1) |
| No chemotherapy | 113 (22) | 44 (17) | 157 (20) |
| Characteristics . | Training cohort (n = 522) . | Validation cohort (n = 262) . | Total cohort (N = 784) . |
|---|---|---|---|
| Age, y | |||
| Median (range) | 79 (70-100) | 78 (70-93) | 79 (70-100) |
| 70-74 | 132 (25) | 70 (27) | 202 (26) |
| 75-79 | 137 (26) | 79 (30) | 216 (28) |
| 80-84 | 149 (29) | 68 (26) | 217 (28) |
| ≥85 | 104 (20) | 45 (17) | 149 (19) |
| Sex | |||
| Female | 248 (48) | 131 (50) | 379 (48) |
| Male | 274 (52) | 131 (50) | 405 (52) |
| Stage (Ann Arbor) | |||
| I | 103 (20) | 44 (17) | 147 (19) |
| II | 132 (25) | 67 (25) | 199 (25) |
| III | 78 (15) | 38 (15) | 116 (15) |
| IV | 206 (40) | 111 (43) | 317 (41) |
| Missing | 3 | 2 | 5 |
| LDH | |||
| Normal | 227 (45) | 112 (46) | 339 (46) |
| Elevated | 273 (55) | 131 (54) | 404 (54) |
| Missing | 22 | 19 | 41 |
| ECOG PS | |||
| 0 | 119 (23) | 38 (15) | 157 (21) |
| 1 | 142 (28) | 88 (36) | 230 (30) |
| 2 | 118 (23) | 55 (22) | 173 (23) |
| 3 | 104 (21) | 51 (21) | 155 (20) |
| 4 | 27 (5) | 15 (6) | 42 (6) |
| Missing | 12 | 15 | 27 |
| Extranodal sites | |||
| 0-1 | 401 (77) | 198 (76) | 599 (77) |
| ≥ 2 | 118 (23) | 63 (24) | 181 (23) |
| Missing | 3 | 1 | 4 |
| IPI score | |||
| Low (1) | 107 (22) | 43 (18) | 150 (21) |
| Low-intermediate (2) | 93 (19) | 61 (26) | 154 (21) |
| High-intermediate (3) | 130 (26) | 54 (23) | 184 (25) |
| High (4-5) | 162 (33) | 78 (33) | 240 (33) |
| Missing | 30 | 26 | 56 |
| ADL | |||
| Independent | 375 (72) | 184 (71) | 559 (72) |
| Dependent | 146 (28) | 75 (29) | 221 (28) |
| Missing | 1 | 3 | 4 |
| CCI | |||
| 0-1 | 311 (60) | 173 (66) | 484 (62) |
| 2 | 106 (20) | 39 (15) | 145 (19) |
| ≥3 | 104 (20) | 50 (19) | 154 (20) |
| Missing, n | 1 | 0 | 1 |
| GNRI | |||
| Absent/low | 300 (63) | 135 (60) | 435 (61) |
| Moderate | 113 (24) | 46 (20) | 159 (23) |
| Severe | 64 (13) | 45 (20) | 109 (16) |
| Missing | 45 | 36 | 81 |
| BMI, kg/m2 | |||
| ≥25 | 271 (58) | 119 (53) | 390 (56) |
| <25 | 198 (42) | 104 (47) | 302 (44) |
| Missing, n | 53 | 39 | 92 |
| Albumin | |||
| ≥36 g/L | 283 (55) | 132 (53) | 415 (54) |
| <36 g/L | 235 (45) | 116 (47) | 351 (46) |
| Missing, n | 4 | 14 | 18 |
| Treatment regimen | |||
| R-CHOP like* | 313 (60) | 169 (65) | 482 (62) |
| R-CHOP > 80% | 202 (39) | 103 (39) | 305 (39) |
| R-CHOP ≤ 80% | 111 (21) | 65 (25) | 176 (22) |
| Missing, n | 0 | 1 | 1 |
| Anthracycline-free regimen† | 96 (18) | 49 (19) | 145 (19) |
| Trofosfamide (Ixoten) | 51 (10) | 18 (7) | 69 (9) |
| R-COP | 36 (7) | 27 (10) | 63 (8) |
| R-CEOP | 3 (0.5) | 1 (0.5) | 4 (0.5) |
| Other‡ | 6 (1) | 3 (1) | 9 (1) |
| No chemotherapy | 113 (22) | 44 (17) | 157 (20) |
Unless otherwise noted, data are n (%).
LDH, lactate dehydrogenase;R-COP, rituximab, cyclophosphamide, vincristine, prednisone; R-CEOP, rituximab, cyclophosphamide, etoposide, vincristine, prednisone.
Includes 3 patients treated with R-CHP: rituximab, cyclophosphamide, doxorubicin, prednisone , 5 patients treated with R-EPOCH: rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and 1 patient treated with the GMALL2002 regimen.
All chemotherapy regimens without anthracycline.
Other: cyclophosphamide (n = 3), bendamustine + rituximab (n = 2), and R-IME: rituximab, ifosfamide, etoposide, TEMODAL (temozolomide), gemcitabine + rituximab (n = 1), and vincristine (n = 1 each).